Home

Schizophrenia

Read time: 3 min

Congress highlights

Can people with ultra-high risk of psychosis benefit from cognitive remediation?

The FOCUS study failed to show neuro- and social-cognitive benefits of cognitive remediation in...

Read time: 2 min

Congress highlights

Digital technology may support sustained long-term recovery in first episode psychosis

Evolving technology can offer people with first episode psychosis personalized treatment when they...

Read time: 3 min

Congress highlights

Opportunities to improve global mental health

Actions to improve global mental health include development and use of a common language to...

Read time: 3 min

Satellite symposium

Long-acting injectables together with medical team training may facilitate functional recovery

Early use of long-acting injectables together with targeted staff training may facilitate ...

Read time: 2 min

Satellite symposium

Early onset schizophrenia needs patient-specific management

Early diagnosis and effective, well-tolerated treatment of early-onset schizophrenia are crucial to...

Read time: 3 min

Satellite symposium

Why use of long acting injectables is an urgent issue

Long acting injectable antipsychotics are often withheld until later stages of schizophrenia, but...

Read time: 2 min

Congress highlights

Real world study casts new light on potential of polypharmacy

The fact that a high number of patients with schizophrenia are treated with more than one...

Read time: 3 min

Congress highlights

The sooner the better: Early detection and intervention in psychosis

Early detection and intervention services for patients with psychosis are at different stages of...

Read time: 3 min

Schizophrenia: more same than different to neurodevelopmental disorders?

Rather than a discrete entity, schizophrenia sits on a neurodevelopmental continuum of disorders...

Neurotoriun

Neurotorium is your new point of reference for educational content on psychiatry, neurology, and neuroscience.

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

Progress in Mind Belux

Accept Cancel

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intended for health care professionals.

All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country